腹腔热灌注化疗治疗胃癌腹膜转移的安全性及有效性单中心临床研究

doi:10.3969/j.issn.1005-6483.2020.05.007

摘要/Abstract

摘要： 目的:探讨腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy，HIPEC）治疗胃癌腹膜转移（gastric cancer of peritoneal carcinomatosis，GCPC）的安全性和有效性。方法:2016年6月～2019年1月我院收治的GCPC病人67例，根据治疗方式不同分为两组，HIPEC组46例，于术后行HIPEC治疗；非HIPEC组21例，术后未行HIPEC治疗。比较两组病人的治疗相关并发症和生存数据，分析影响GCPC病人预后的相关因素。结果:HIPEC治疗对病人的术后血象指标和术后并发症均无显著改变。联合肿瘤细胞减灭术（cytoreductive surgery，CRS）和HIPEC治疗的病人，中位生存期优于仅行CRS治疗者（14个月 vs 9个月，P=0.012）。多因素分析提示，术后早期行HIPEC治疗及术后行全身静脉化疗和（或）放疗能为完成肿瘤细胞减灭术的GCPC病人带来生存获益，术前血清CA724升高是预后的独立危险因素。结论:对于实现肉眼可见完全肿瘤细胞减灭的胃癌腹膜转移病人，CRS+HIPEC的治疗策略并不会增加治疗相关并发症的发生，同时能够延长病人生存期。

关键词: 腹腔热灌注化疗, 胃癌, 腹膜转移, 肿瘤细胞减灭术, 安全性

Abstract: Objective:To evaluate the clinical efficacy and safety of hyperthermic intraperitoneal chemotherapy，HIPEC in the treatment of gastric cancer with peritoneal carcinomatosis，GCPC.Methods:The clinical data of 67 patients with GCPC who were treated by surgery and confirmed by pathology were retrospectively analyzed.Among them，46 patients undergo HIPEC treatment，the other 21 patients refuse HIPEC treatment.Treatmentrelated complications and postoperative survival data were compared to analyze the factors involved in the prognosis of GCPC patients.Results:There was no significant difference with respect to treatmentrelated serious adverse event，SAE.Patients who received CRS CCR（0～1）（n=24）and HIPEC（n=15）at the same time had a median OS of 14 months，while those who receive CRS alone（n=9）had a median OS of 6 months（P=0.012）.Multivariate analysis suggested that early HIPEC treatment and regular postoperative chemotherapy bring survival benefit for GCPC patients who underwent CRS CCR（0～1），the elevation of serum CA724 were independent risk factor to postoperative survival time of GCPC.Conclusion:For patients with peritoneal metastasis of gastric cancer who achieve complete tumor cell extinction visible to the naked eye，the treatment strategy of CRS+HIPEC will not increase the occurrence of treatation-related complications，and at the same time can prolong the survival of patients.

Key words: hyperthermic intraperitoneal chemotherapy, gastric cancer, peritoneal metastasis, cytoreduction, safety and efficacy

吴川清, 李源, 王点石, 杜周元, 吴轲, 高金波, 王征, 王国斌, 陶凯雄. 腹腔热灌注化疗治疗胃癌腹膜转移的安全性及有效性单中心临床研究[J]. 临床外科杂志, 2020, 28(5): 424-428.

参考文献

相关文章 15

[1]	秦龙〓李婷. 肝脏悬吊技术在腹腔镜胃癌根治术中的应用[J]. 临床外科杂志, 2020, 28(6): 557-559.
[2]	狄子杨, 唐强, 狄茂军等. 腹腔热灌注化疗治疗晚期结直肠癌的疗效分析[J]. 临床外科杂志, 2020, 28(5): 433-436.
[3]	宋兴超, 路要武, 吴超等. 加速康复外科在全腹腔镜远端胃癌D2根治术中的应用[J]. 临床外科杂志, 2020, 28(5): 456-459.
[4]	汪东文, 樊巍巍, 乔庆等. 加速康复外科对老年胃癌病人术后谵妄发生的影响[J]. 临床外科杂志, 2020, 28(5): 480-482.
[5]	李强, 王文佳, 宋志强, 李胜文 . 输尿管软镜钬激光碎石取石术应用于＞2cm上尿路结石的临床疗效和安全性[J]. 临床外科杂志, 2020, 28(2): 116-119.
[6]	张颖, 张燕, 王晶晶. 择期手术前禁食禁饮时间的Meta分析[J]. 临床外科杂志, 2020, 28(2): 151-154.
[7]	曾国祥, 黄修仿 . 腹腔镜微创根治术联合术中腹腔热灌注化疗对老年大肠癌病人血清TGF-β1及Periostin水平的影响[J]. 临床外科杂志, 2020, 28(2): 177-179.
[8]	梁寒. 胃癌肝转移诊断与综合治疗中国专家共识解读[J]. 临床外科杂志, 2020, 28(1): 38-40.
[9]	严峻, 柏淳, 李锋, 傅文喜, 余小红. 经皮肝动脉化疗栓塞术联合索拉非尼治疗肝癌的疗效及安全性观察[J]. 临床外科杂志, 2019, 27(8): 668-670.
[10]	周晓飞, 彭金燕, 刘燕. 微创手术在脑出血治疗中的安全性及对病人血清Cys-C、AQP4的影响[J]. 临床外科杂志, 2019, 27(8): 671-673.
[11]	李子禹, 薛侃. 胃癌外科诊疗有感[J]. 临床外科杂志, 2019, 27(5): 361-362.
[12]	郑勇斌. 胃癌根治术中脾门淋巴结清扫的热点和争议[J]. 临床外科杂志, 2019, 27(5): 373-375.
[13]	郭伍斌, 马新, 黎晖. Fbxw7过表达促进mTOR降解并抑制胃癌细胞迁移的研究[J]. 临床外科杂志, 2019, 27(5): 379-382.
[14]	王家欢, 汪洋. 近端胃切除加幽门成形术对近端胃癌病人胃食管反流及营养的影响[J]. 临床外科杂志, 2019, 27(5): 387-389.
[15]	李欣龙, 顾立虎, 祝和攀, 潘军海, 陈玉萍. 加速康复外科理念在腹腔镜胃癌根治术中的应用[J]. 临床外科杂志, 2019, 27(5): 404-407.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed